Abstract: Provided are compounds (and pharmaceutically acceptable non-toxic salt of such compounds) of the formula: in which A and B are C1-C3 alkylene; R1 is C1-C6 alkyl; R2 and R3 are hydrogen or C1-C6 alkyl; U and V are C1-C6 alkyl or halogen; X, Y and Z are hydrogen, C1-C6 alkyl, trifluoromethyl, C1-C6 alkoxy, trifluoromethoxy, halogen, or cyano; and W represents up to three substituents which are C1-C6 alkyl, trifluoromethyl, C1-C6 alkoxy, trifluoromethoxy, halogen, hydroxy, amino, or cyano. These compounds act as modulators of blood glucose levels and are useful for the treatment of diabetes, eating disorders, and obesity. Pharmaceutical compositions and methods of use of the compounds as pharmaceutical agents are also provided.

Abstract: A method, program and system for mapping ASN.1 data to an object model are provided. The invention consists of identifying the start of a data stream and then generating a new object name for the data. Next, the data is parsed to get the identifier and the data length. Then the data's tag type is analyzed. If the tag type is simple, a class diagram is generated for the data and then the source code for the data is generated. If the tag type is not simple, a subroutine is called to further parse the data before generating the class diagram and source code.

Abstract: The present invention allows multiple stops in a complete transmission and retains the history and integrity of the stops, as well as any modifications made by the stop point along the way. The invention works whether the transmission consists of synchronous or asynchronous protocols. The invention is specifically designed to operate when both protocols are present in the same transmission. The invention keeps a history of the stop by chaining SignedData objects together and using the related message digest signed attribute for the linkages. This ability to blend two different protocols is not available in other transmission techniques involving only one hop between entities. The technique of the invention retains the original identity and signature of the original sender, as well as the integrity of the original message.

Abstract: A method, apparatus, and computer implemented instructions for synchronizing time in a network data processing system. A request for time synchronization is received at a target data processing system. A current target time at the target data processing system is placed in a reply. The reply is sent to the source data processing system. A current source time from when the reply is received at the source data processing system is compared to the current target time to generate a comparison. A synchronization factor is generated using the comparison.

Abstract: Disclosed are 1-Azatricyclic-4-benzylpiperazine compounds which are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.

Abstract: Disclosed are 1-Azatricyclic-4-benzylpiperazine compounds which are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.

Abstract: Disclosed are compounds of the formula: 1

Abstract: Disclosed are 1-Azatricyclic-4-benzylpiperazine compounds which are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.

Abstract: Disclosed are compounds of the formula: or pharmaceutically acceptable addition salts thereof wherein: R1, R2, R3 R4 and R5, R6, R7, and R8 represent organic and/or inorganic substituents as defined herein, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.